- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 215/36 - Sulfur atoms
Patent holdings for IPC class C07D 215/36
Total number of patents in this class: 315
10-year publication summary
|
26
|
18
|
23
|
29
|
24
|
21
|
14
|
23
|
19
|
8
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Agios Pharmaceuticals, Inc | 216 |
15 |
| Amgen Inc. | 4074 |
12 |
| Bristol-myers Squibb Company | 4878 |
8 |
| Novartis AG | 10867 |
7 |
| Hinova Pharmaceuticals Inc. | 96 |
7 |
| Jiangsu Hengrui Medicine Co., Ltd. | 706 |
7 |
| Pharmaxis Ltd | 39 |
6 |
| Korea Research Institute of Chemical Technology | 1385 |
5 |
| Oxford Drug Design Limited | 9 |
5 |
| Galapagos NV | 274 |
4 |
| Galderma Research & Development | 405 |
4 |
| National Cancer Center | 320 |
4 |
| The Provost, Fellows, Foundation Scholars, and The Other Members of Board, of The College of The Holy and Undivided Trinity of Queen Elizabeth, Near Dublin | 163 |
4 |
| Southern Research Institute | 210 |
4 |
| The United States Government AS represented by The Department of Veterans Affairs | 1166 |
4 |
| The University of Melbourne | 537 |
4 |
| The University of Queensland | 659 |
4 |
| Inflazome Limited | 85 |
4 |
| AbbVie Global Enterprises Ltd. | 12 |
4 |
| Merck Patent GmbH | 5829 |
3 |
| Other owners | 200 |